Table 1.
Clinical and tumor-related features of GC-positive and GC-negative patients.
| Characteristic | GC-pos | GC-neg | P | ||
|---|---|---|---|---|---|
| N = 126 | N = 173 | ||||
| Age as median (IQR) | |||||
| At diagnosis of primary tumor (years) | 61 (52–68) | 61 (51–70) | 0.792 | ||
| At diagnosis of BM (years) | 63 (56,75–71) | 62.5 (53–72) | 0.406 | ||
| Latency (months) | 12 (0–34.75) | 12 (0–33.5) | 0.312 | ||
| Sex | N | % | N | % | 0.452 |
| Female | 66 | 52.4 | 83 | 47.7 | |
| Male | 60 | 47.6 | 90 | 52.3 | |
| Number of BM as median (IQR) | 3 (1–11) | 2 (1–6) | 0.062 | ||
| Primary tumor | N | % | N | % | 0.437 |
| Lung cancer | 52 | 41.3 | 85 | 49.1 | |
| Non-small cell | 34 | 27.0 | 61 | 35.2 | |
| Small cell | 17 | 13.5 | 24 | 13.9 | |
| Unknown | 1 | 0.8 | – | – | |
| Genitourinary cancer | 20 | 15.9 | 20 | 11.6 | |
| Kidney | 6 | 4.8 | 8 | 4.6 | |
| Prostate | 5 | 4 | 5 | 2.9 | |
| Urothelium | 5 | 4 | 1 | 0.6 | |
| Ovary | 2 | 1.6 | 2 | 1.2 | |
| Testicles | 2 | 1.6 | 2 | 1.2 | |
| Uterus | – | – | 2 | 1.2 | |
| Breast cancer | 18 | 14.3 | 18 | 10.4 | |
| Skin cancer | 11 | 8.7 | 20 | 11.6 | |
| Melanoma | 11 | 8.7 | 18 | 10.4 | |
| Merkel cell carcinoma | – | – | 1 | 0.6 | |
| Squamous cell carcinoma | – | – | 1 | 0.6 | |
| Gastrointestinal cancer | 14 | 11.1 | 17 | 9.8 | |
| Colon | 6 | 4.8 | 5 | 2.9 | |
| Rectum | 2 | 1.6 | 5 | 2.9 | |
| Esophagus | 2 | 1.6 | 4 | 2.3 | |
| Gastroesophageal junction | 2 | 1.6 | 2 | 1.2 | |
| Stomach | – | – | 1 | 0.6 | |
| Neuroendocrine | 1 | 0.8 | – | – | |
| Cholangiocellular carcinoma | 1 | 0.8 | – | – | |
| Cancer of unknown primary | 6 | 4.8 | 10 | 5.8 | |
| Sarcoma | 5 | 4 | 2 | 1.2 | |
| Head and Neck | – | – | 1 | 0.6 | |
| Thyroid | – | – | 1 | 0.6 | |
BM, brain metastases; GC-neg, patients who did not receive glucocorticoids; GC-pos, patients in whom glucocorticoids were given.